Premium
Activated CD4+ and CD8+ T‐lymphocytes in Newly Diagnosed Type 1 Diabetes: a Prospective Study
Author(s) -
Buschard K.,
Damsbo P.,
Röpke C.
Publication year - 1990
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/j.1464-5491.1990.tb01347.x
Subject(s) - medicine , diabetes mellitus , cd8 , type 2 diabetes , prospective cohort study , type 1 diabetes , cd4 cd8 ratio , immunology , endocrinology , lymphocyte subsets , immune system
Peripheral lymphocytes from 13 Type 1 diabetic patients (age 28 ± 11 (±SD) years) were studied at diagnosis, and 1 month and 7 months later. The lymphocytes were labelled with phycoerythrin‐conjugated anti‐HLA‐DR antibody and/or fluorescein‐conjugated OKT4 or OKT8 antibody, and then studied using a double channel flow‐cytometer. The overall percentage of activated T‐lymphocytes (CD4+ + CD8+ cells) was (mean ± SE) 3.1 ± 0.5% at diagnosis, 2.1 ± 0.3% at 1 month and 2.2 ± 0.5% at 7 months test. The percentages at diagnosis and 1 month were higher than in 12 healthy control subjects (1.0 ± 0.2%, p < 0.001 and p < 0.01, respectively). Among the CD4+ cells the percentage of activated cells fell from diagnosis (2.8 ± 0.7%), to 1 month (1.5 ± 0.3%, p < 0.05), and 7 months (1.5 ± 0.4%, p < 0.05), whereas among the CD8+ cells they remained unchanged (3.3 ± 0.6, 2.5 ± 0.5 and 3.1 ± 0.6%). The percentage of activated CD4+ cells at diagnosis, and of CD8+ cells at all times, were higher ( p < 0.02) than in control subjects (CD4+, 0.8 ± 0.2%; CD8+, 1.2 ± 0.2%). In conclusion, the activated T‐lymphocytes present in Type 1 diabetic patients at diagnosis are equally increased among CD4+ and CD8+ cells, but after 7 months the increase is predominantly in CD8+ cells.